ORKA (Oruka Therapeutics) Earnings per Share (Diluted) : $ (TTM As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Oruka Therapeutics Earnings per Share (Diluted)?

Oruka Therapeutics's Earnings per Share (Diluted) for the six months ended in Dec. 2024 was $0.00.

Oruka Therapeutics's EPS (Basic) for the six months ended in Dec. 2024 was $0.00.

Oruka Therapeutics's EPS without NRI for the six months ended in Dec. 2024 was $0.00.

Oruka Therapeutics Earnings per Share (Diluted) Historical Data

The historical data trend for Oruka Therapeutics's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oruka Therapeutics Earnings per Share (Diluted) Chart

Oruka Therapeutics Annual Data

Trend

Dec24

Earnings per Share (Diluted)

Oruka Therapeutics Semi-Annual Data
	Dec24
Earnings per Share (Diluted)	-

Competitive Comparison of Oruka Therapeutics's Earnings per Share (Diluted)

For the Biotechnology subindustry, Oruka Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oruka Therapeutics's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oruka Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Oruka Therapeutics's PE Ratio falls into.

Save Embed

;

Save Embed

;

Oruka Therapeutics Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Oruka Therapeutics's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2024 is calculated as

Diluted Earnings Per Share (A: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(0	-	0)	/	0
	=

Oruka Therapeutics's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2024 is calculated as

Diluted Earnings Per Share (Q: Dec. 2024 )	=	(Net Income	-	Preferred Dividends	/	Shares Outstanding (Diluted Average)
	=	(0	-	0)	/	0
	=

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.

Oruka Therapeutics (NAS:ORKA) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Oruka Therapeutics Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Oruka Therapeutics's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Oruka Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (NAS:ORKA) » Definitions » Earnings per Share (Diluted)

Comparable Companies

Traded in Other Exchanges

HQ1:Germany

Address

855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025

Website

https://www.orukatx.com

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.